索拉非尼联合用药在甲状腺未分化癌中的研究现状  

Research status on sorafenib combined medication in anaplastic thyroid cancer

作　　者：杨天乐 徐丽莎 符宇涛 王姝婷 唐任绮 金欣[1] YANG Tian-le;XU Li-sha;FU Yu-tao;WANG Shu-ting;TANG Ren-qi;JIN Xin(Medical College,Shaoxing University,Shaoxing 312000,Zhejiang Province,China)

机构地区：[1]绍兴文理学院医学院,浙江绍兴312000

出　　处：《中国临床药理学杂志》2021年第11期1459-1462,共4页The Chinese Journal of Clinical Pharmacology

基　　金：国家科技重大专项“十三五”计划课题资助项目(2018ZX10305410-410-007);浙江省基础公益研究计划课题资助项目(LGF18H160014);绍兴文理学院学生科研基金资助项目(医学院202018)。

摘　　要：甲状腺未分化癌是恶性程度最高的甲状腺癌。索拉非尼可通过多途径发挥抑癌作用,索拉非尼联合用药治疗甲状腺未分化癌显示出相对积极的结果,治疗效果明显优于单药。本文将对索拉非尼联合用药治疗甲状腺未分化癌的研究进展进行综述,以期能为甲状腺未分化癌的有效治疗提供参考依据。Anaplastic thyroid cancer is the most malignant thyroid cancer. Sorafenib can exert anti-cancer effects through multiple channels. The combination of sorafenib in the treatment of anaplastic thyroid cancer has shown relatively positive results, and the therapeutic effect is significantly better than that of single drug. This article will review the research progress of sorafenib combination therapy for anaplastic thyroid cancer, in order to provide a reference for effective treatment of anaplastic thyroid cancer.

关 键 词：索拉非尼 联合用药 甲状腺未分化癌 协同作用 调节信号通路 

分 类 号：R979.1[医药卫生—药品]